Cellular therapy · BLA
Tregzi NDC 85866-223
allogeneic regulatory t cell immunotherapy with hspc and t cells-vldq · Kit · Orca Biosystems Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 85866-223-04 | 85866022304 | 1 KIT in 1 CARTON (85866-223-04) * 100 mL in 1 BAG (85866-124-01) * 1 BAG in 1 CARTRIDGE (85866-126-02) / 15 mL in 1 BAG (85866-126-01) * 1 BAG in 1 CARTON (85866-127-02) / 30 mL in 1 BAG (85866-127-01) * 100 mL in 1 BAG (85866-125-01)Marketed from Jun 30, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tregzi
- Generic name (nonproprietary)
- allogeneic regulatory t cell immunotherapy with hspc and t cells-vldq
- Dosage form
- Kit
- Labeler
- Orca Biosystems Inc.NDC labeler code 85866
- Product type
- Cellular therapy
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 125868
- Marketing start
- Listing expires
- Identifiers
- Product ID 85866-223_ffffa405-7551-4adc-9a7c-98750b100095SPL ID ffffa405-7551-4adc-9a7c-98750b100095SPL set ID 2157e11b-87c3-4d54-a225-81b341e4e21aRxCUI 2747373, 2747379
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N485866022304followed by a unit qualifier and the quantityPackage 85866-0223-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
TREGZI is indicated for use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease-free survival, in the treatment of adults with hematological malignancies. TREGZI™ is an allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cells and T cells indicated for use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGVHD)-free survival, in the treatment of adults with hematological …
Excerpt only. Read the full label for complete information.
About NDC 85866-223
- What is NDC 85866-223?
- 85866-223 is the product NDC for Tregzi kit, listed with the FDA by Orca Biosystems Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Tregzi (Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq).
- Who is the labeler?
- Orca Biosystems Inc., NDC labeler code 85866. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Tregzi?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.